for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UPDATE 1-Ipsen profits rise on specialty care drugs

* Ipsen H1 recurring adj consolidated net profit 80.7 mln eur

* Confirms 2010 financial goals

(Adds detail from statement)

PARIS, Aug 31 (Reuters) - French drugmaker Ipsen IPN.PA posted a 7 percent rise in first-half earnings on the back of growing sales of specialty care drugs, such as for treating cancer, and kept its goals for the year.

Ipsen expects recurring adjusted earnings per share to match last year and group revenue to grow 3 to 5 percent as a rise in specialty care sales offsets a drop in primary care sales following government healthcare spending cuts.

Recurring adjusted consolidated profit reached 80.7 million euros ($102.7 million) in the first half, Ipsen said in a statement on Tuesday.

Group sales rose 6.3 percent to 553.9 million euros with sales of specialist care products climbing 15.6 percent to 352.1 million. Sales from primary care, referring to drugs prescribed mostly by general practitioners, fell nearly 7 percent.

“In a difficult economic and changing pharmaceutical environment in its historical European markets, the group continues its geographic expansion in the U.S. and in emerging markets,” Chief Executive Jean-Luc Belingard said.

Ipsen has been expanding in the United States. It launched its first product, Dysport, on its own as a muscle relaxant and in a partnership as an anti-wrinkle treatment that competes with Allergan's AGN.N Botox.

It also sealed a haemophilia partnership with Inspiration Biopharmaceuticals in the world’s biggest drug market. ($1=.7861 Euro) (Reporting by Caroline Jacobs; Editing by James Regan)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up